Jasper Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
JSPR Nasdaq 2836 jaspertx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Jasper Therapeutics, Inc.

Jasper Therapeutics reports updated data from briquilimab studies - Jan 9th, 2026 5:15 am
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - Jan 8th, 2026 5:00 am
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - Jan 7th, 2026 2:30 pm
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation - Dec 2nd, 2025 5:00 am
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation - Dec 1st, 2025 2:30 pm
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Nov 20th, 2025 3:13 am
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 10th, 2025 6:00 am
Jasper Therapeutics to Present at Upcoming Investor Conferences - Nov 4th, 2025 6:00 am
Positive Signs As Multiple Insiders Buy Jasper Therapeutics Stock - Oct 10th, 2025 4:24 am
Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants - Sep 18th, 2025 2:08 pm
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 13th, 2025 2:05 pm
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway - Jul 9th, 2025 6:00 am
Jasper Therapeutics to Halt Asthma Study After Drug Batch Issue; Shares Fall Pre-Bell - Jul 7th, 2025 7:02 am
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria - Jul 7th, 2025 5:30 am
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - Jun 14th, 2025 8:00 am
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress - Jun 3rd, 2025 6:00 am
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely - May 29th, 2025 4:58 am
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 12th, 2025 2:05 pm
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - Mar 1st, 2025 10:45 am
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting - Feb 28th, 2025 6:00 am